How should an incidentally discovered liver mass on a cardiac Doppler study be evaluated and managed in a young patient?

Evaluation of an Incidental Liver Mass on Cardiac Doppler in a Young Patient

An incidentally discovered liver mass on cardiac Doppler in a young patient should be characterized with either multiphase contrast-enhanced CT or contrast-enhanced MRI (with and without IV contrast), with MRI preferred when available due to superior lesion characterization and absence of ionizing radiation. 1

Initial Imaging Strategy Based on Lesion Size

For Lesions ≥1 cm

The American College of Radiology designates both multiphase contrast-enhanced CT and contrast-enhanced MRI as "usually appropriate" (rating 7-9) and equivalent first-line options for characterizing liver lesions >1 cm discovered on ultrasound in patients with normal liver and no known malignancy. 1

• MRI abdomen without and with IV contrast is the preferred modality because it provides superior tissue characterization, can detect premalignant nodules, and avoids ionizing radiation—particularly important in young patients. 2

• Multiphase CT abdomen with IV contrast (arterial, portal-venous, and delayed phases) is an acceptable alternative when MRI is unavailable, contraindicated, or technically limited. 1

• Contrast-enhanced ultrasound (CEUS) can correctly characterize approximately 95% of liver lesions overall and distinguish benign from malignant in 90% of cases, making it a viable option when CT or MRI are not immediately accessible. 1

For Lesions <1 cm

When subcentimeter lesions are identified in a young patient without chronic liver disease or malignancy history, observation with repeat imaging in 3-6 months is reasonable. 2

• However, if any clinical concern exists (family history, symptoms, abnormal liver function tests), proceed directly to MRI with and without contrast rather than observation. 2

Critical Clinical Context to Assess

Risk Stratification

Before ordering advanced imaging, obtain targeted history and laboratory work-up to stratify risk:

• Liver function tests (AST, ALT, alkaline phosphatase, bilirubin, albumin) should be obtained to detect hepatocellular injury or cholestasis. 2

• Complete blood count with differential is essential to identify cytopenias that may signal portal hypertension or hematologic malignancy. 2

• Query for chronic liver disease risk factors: alcohol use, viral hepatitis exposure, metabolic syndrome, autoimmune disease, family history of liver disease. 2

• In patients <40 years with unexplained hepatomegaly, serum ceruloplasmin and 24-hour urinary copper should be obtained to exclude Wilson disease, which can present with subclinical cirrhosis. 2

Physical Examination Findings

Examine specifically for:

• Stigmata of chronic liver disease (spider angiomas, palmar erythema, jaundice). 2
• Palpable splenomegaly or hepatomegaly. 2
• Signs of portal hypertension (ascites, caput medusae). 2

Common Benign Lesions in Young Patients

Benign focal liver lesions occur in up to 15% of patients, with the most common being cysts, hemangiomas, and focal nodular hyperplasia (FNH). 1

• Hepatocellular adenoma is less common but clinically important in young patients, particularly women using oral contraceptives, as certain molecular subtypes carry malignant potential. 3

• Even in patients with known primary malignancy elsewhere, benign lesions unrelated to malignancy are found in nearly 30% of cases. 1

Timeline for Follow-Up

Dedicated contrast-enhanced imaging (multiphase CT or MRI) should be completed within 4-6 weeks when focal lesions are identified or initial laboratory results are abnormal. 2

Subspecialty consultation with hepatology should occur within 4-8 weeks if:

• Liver function tests are abnormal. 2
• Imaging suggests cirrhosis or chronic liver disease. 2
• The lesion remains indeterminate after advanced imaging. 2

Common Pitfalls to Avoid

Do not assume all incidental liver findings in young patients are benign simply due to age. While benign lesions predominate, hepatocellular adenomas with malignant potential, fibrolamellar hepatocellular carcinoma, and metabolic diseases can present in youth. 1

Do not order non-contrast CT or single-phase CT for lesion characterization—these modalities cannot adequately characterize liver masses and will necessitate repeat imaging with proper contrast protocols. 1

Avoid liver biopsy for suspected hemangiomas or vascular lesions due to bleeding risk; these should be characterized non-invasively with contrast-enhanced imaging. 2

In patients with any suggestion of chronic liver disease (even subclinical), apply LI-RADS criteria for lesion evaluation, as the differential diagnosis shifts significantly toward hepatocellular carcinoma and dysplastic nodules. 1